Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    illegally

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    Please explain how the shorts magically drive the price down?

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    The stock can easily come back to 3.30-3.40 and the uptrend will still be intact. Some weak longs need to shaken out. Stock needs to go to wholesale prices before it hits retail.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    I added to my position yesterday on the bottom and will add more today.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    Agreed Bill. I would be a little worried if we had a trend of a few days like this. However, a little pull back and consolidation is good after a 90% run up in a just few weeks. I think we will resume our trend back up soon. I am still targeting $6-8 before results.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    Agreed. Today's action is the shorts trying to drive it down. They start selling short and people think something's wrong and they sell creating more downward pressure on the price.

    I would not be surprised to see a hit piece put out by one of the short shills, including this board's resident short tout Bill Williams.

    This has always been how the shorts have played the game and tried to manipulate the stock price.

    This is a major buying opportunity for those who believe the odds of a positive data read out from Pivot is likely. The market cap and resulting pps after positive data and the market discounting a subsequent deal with pharma or another pool of private capital will be many multiples of where it is now.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    It has indeed been volatile, even on no news. Just seemed worth noting today as it's 2x 3mth-avg vol. If the trend over the next 6-8 weeks repeats the prior run ups to results, great. We should have a few nice upside days on heavy volume.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    Todays action is very similar to price action on the upward trend during the last couple of run ups before results. Its never a straight shot up and there are still plenty of shorts who will try and hold this down. There have been many days like this in the past.

  • Reply to

    technicals on Ampe?

    by honeymoonerz Apr 27, 2016 5:22 AM

    Big drop on modestly high volume today. Does not appear to be connected to biotech indexes.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    How exactly does one "slip some bait and switch past their investors." ? what a moronic statement. It's not even properly written. But yet we longs should all sell now because you posted this. Go back into your hole Roger. This board is for those with an IQ above your age.
    BTW, how about the 68% increase over the past 30 days? One can't help but love that.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    It's good to see them doing some publications and taking part in industry events. The below excerpt is interesting. It looks like a heads up to something very cool coming soon. I suspect this is all part of the 'valuation' game they are in.

    Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports Ampion™ up-regulates an important prostaglandin molecule (15d-PGJ2) associated with healing and resolution of inflammation in peripheral blood monocytes. These three publications in peer reviewed scientific forums further validate the scientific rationale for the use of the low molecular weight fraction of human serum albumin (Ampion™) in treating inflammatory conditions such as osteoarthritis. Several other scientific publications are in progress."

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    They did synovial fluid analyses in SPRING and STRUT for both anti-inflammatory and SC stimulatory proteins, with the purpose of STRUT to look for any healing substantiated by MRI. The paper may refer to the former. It would require release of STRUT results to see if those anti-inflammatory protein expression profiles correlated with SPRING.

    From Bar Or's comments about STRUT on a CC, there was no evidence of significant cartilage growth. Whatever the in vitro and synovial fluid analyses are you are correct in that the only thing that matters is translation to significantly less pain than saline. Let's hope we get at least the 0.25pt difference between arms again. A lot of money on a seemingly small number in a subjective test with an active placebo.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    That's true regarding regeneration and though he does mention healing in his statement, just given the titles of the three publications one adressing COX-2 pathways, one NF-kB inhibition and the other 15d-PGJ2 up-regulation I would assume that Ampio's focus is towards the MOA of anti-inflammation with less focus on regeneration and healing. which will hopefully be validated by this current trial.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    I need to read the manuscript in detail. The important point is whether a clinically relevant effect can be seen. All drug compounds that advance from hit to lead show in vitro and cellular activities on relevant targets. Efficacy in disease models actually proves it can improve a condition in vivo (which cannot be done with Ampion) and leads to possible clinical trials.

    So, they would need to prove that a clinically relevant effect could be seen with an approved dosage. Ampion showed cartilage growth in situ, but there was no evidence of it from STRUT. Still, there is some value with non-clinical MOA studies.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    "ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms of action (MOA) of Ampion™."

    Peer-reviewed scientific forums, not journals, is misrepresentation of the peer reviewed journals standard.
    "Peer Review: Publication’s Gold Standard
    ...Scientific journals catalog the contributions, thoughts, and opinions of researchers, investigators, and experts in the field. Authors consider the reputation and quality of a journal prior to submitting a manuscript for consideration.

    ...The goal of peer review is to determine if an article should or should not be published and to improve the article before publication (Neale & Bowman, 2006). It is a process that entails filtering out manuscripts that are misleading, irrelevant, inaccurate, or that contain potentially harmful content (Kumar, 2009)."

    Two posters in the halls at a convention for a couple of days is playing with the term "publication".
    AAST Publishes the Journal of Trauma and Acute Care Surgery. AMPE's efforts were either not submitted or were rejected for publication is the Journal. See instructions for Abstract submission at the conventions website.

    You gotta wonder what's in it for a couple of slick willies trying to slip some bait and switch past their investors.

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    It's good to see them doing some publications and taking part in industry events. The below excerpt is interesting. It looks like a heads up to something very cool coming soon. I suspect this is all part of the 'valuation' game they are in.

    Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports Ampion™ up-regulates an important prostaglandin molecule (15d-PGJ2) associated with healing and resolution of inflammation in peripheral blood monocytes. These three publications in peer reviewed scientific forums further validate the scientific rationale for the use of the low molecular weight fraction of human serum albumin (Ampion™) in treating inflammatory conditions such as osteoarthritis. Several other scientific publications are in progress."

  • Reply to

    REGN fasinumab

    by billwilliams836 May 2, 2016 4:55 PM

    The new publications appear to back up an anti-inflammatory MOA of Ampion, at least in cell-culture. There still isn't any publication on possible healing in human OAK (STRUT) but they did state more in progress. This MOA has a longer term advantage over immediate pain relief MOAs, even though they can be stronger effects.

  • REGN fasinumab reported Phase 2/3 for moderate-to-severe osteoarthritis of the hip or knee

    10-point (NRS) WOMAC, baseline = 6.3 4 arms (3 dose, 1 placebo), N=421
    4 subcutaneous injections (Wk 0-Wk12) Endpoint at Wk 16
    All doses (1,3,6,9mg) led to ca. -3.3 vs placebo -2.3 with excellent-to-modest p-values (0.0001-0.03)

    So, 52% pain reduction vs 37% for placebo. Not all that impressive considering it was 4xMI and the endpoint was only 4 wks after the last injection. Fasinumab has had serious SE in the past. It is subQ vs IA injection, but Ampion is a much safer product based on available data.

  • Last four trading days displays upwards trend toward the end of the trading day.

  • Reply to

    32 cents till 52 week lowwwwww.

    by cheukster Apr 29, 2016 10:32 AM

    The 52 week low is $1.69. Go away troll.

Must Watch
AMPE
3.77-0.02(-0.53%)May 27 4:02 PMEDT